Status:

COMPLETED

Study to Evaluate Bioactive Peptides' Effect on Digestive Discomfort Symptoms of the Elderly

Lead Sponsor:

Nuritas Ltd

Collaborating Sponsors:

Atlantia Food Clinical Trials

Conditions:

Abdominal Pain

Eligibility:

All Genders

65-75 years

Phase:

NA

Brief Summary

This trial will investigate the potential of a bioactive peptide to reduce symptoms of digestive discomfort in a generally healthy elderly population. Participants will consume the bioactive peptide f...

Detailed Description

Forty subjects aged between 65 and 75 with self-reported symptoms of digestive discomfort will be randomised. Subjects will be randomised to receive either the Bioactive peptide or placebo for a total...

Eligibility Criteria

Inclusion

  • Be able to give written informed consent
  • Be between 65 and 75 years of age (inclusive)
  • Have symptoms of digestive pain \& discomfort
  • Have a Fried Frailty score of \<2
  • Have a Short physical performance battery (SPPB) score of \>5 and \<10
  • Have a Mini Mental State Exam (MMSE) score \>24
  • Have low or moderate activity according to the IPAQ short form
  • Have a BMI \<30 kg/m2
  • Be in good general health.

Exclusion

  • Are less than 65 and greater than 75 years of age
  • Are severely immunocompromised (HIV positive, transplant Subject, on antirejection medications, on a steroid for \>30 days.
  • Have a diagnosis of Irritable Bowel Syndrome
  • Is taking a high dose of statins and/or has changed had their dose modified in the previous 6 months
  • Is experiencing muscle pain, soreness or muscle loss in the previous 6 months
  • Has a history of drug and / or alcohol abuse at the time of enrolment
  • Has changed their dietary habit within the preceding month
  • Has a known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon and significant systemic disease
  • Subject currently involved in any other clinical trial or having participated in a trial within the preceding 90 days
  • Has known allergy to components of the test product
  • Use of anti-inflammatory steroid medications, anticoagulants, current/recent (3 months) history of anabolic steroid, corticosteroid or estrogen use, testosterone replacement therapy (ingestion, injection, or transdermal), or any anabolic steroid
  • Has any concurrent medical or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements

Key Trial Info

Start Date :

June 14 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 20 2017

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04450979

Start Date

June 14 2016

End Date

January 20 2017

Last Update

April 14 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.